PSP Research’s Legend Biotech LEGN Stock Holding History

PSP Research’s Portfolio LEGN Stock Details LEGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-12,000	Closed	-$217K	–	84
2026 Q1	$217K	Sell	12,000 -12,397	-51%	-$236K	0.15%	68
2025 Q4	$530K	Buy	+24,397	New	+$699K	0.46%	42

Other funds holding LEGN

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.56% 1-Year Est. Return

PSP Research's LEGN Position: Q2 2026 in Review

PSP Research sold out of Legend Biotech (LEGN) in Q2 2026, closing a stake of 12,000 shares — an estimated $217K sold.

PSP Research first reported a position in LEGN in Q4 2025 and held it in 2 quarters. The position peaked at $530K in Q4 2025. 218 funds tracked by Wall St. Rank hold LEGN as of Q2 2026.

PSP Research reported no remaining Legend Biotech position as of Q2 2026 after selling out during the quarter.
PSP Research sold 12,000 Legend Biotech shares in Q2 2026, an estimated $217K.
PSP Research first reported a position in Legend Biotech in Q4 2025 and held it in 2 quarters.
PSP Research's Legend Biotech position peaked at $530K in Q4 2025.
218 funds tracked by Wall St. Rank held Legend Biotech as of Q2 2026.

Based on PSP Research's 13F filing for Q2 2026, filed 9 Jul 2026.